Paller said that dupilumab can effectively treat the immune systems of these children with eczema, reduce their series of allergic problems, and improve their lives; situational picture. (Image taken from potAC)
[Sianel Iechyd / Adroddiad Cynhwysfawr]Eczema is a type of dermatitis that can make the skin red, dry and itchy, seriously affecting the lives of patients and their families. According to statistics, more than 19% of children under the age of 6 suffer from eczema. Regarding eczema in young children, a study in the United States used the first biological drug, rather than an immunosuppressive drug, to treat young children with eczema between the ages of 6 months and 5 years. The study was published in the renowned medical journal The Lancet.
According to Science Daily, a course of dopilumab, a biologic drug that targets the immune pathway of allergy, is the first treatment for any skin condition, including eczema, in children aged 6 months. , a placebo-controlled trial. The study, conducted at 31 sites in Europe and North America, helped more than half of the young children reduce eczema symptoms by 75%, resulting in less itching and better sleep.
Please read on…
Debilitating pruritus in children can lead to sleep disturbances, poor neurodevelopment and, on average, a full night of sleep a week, said study author Amy Paller, chair of dermatology at Northwestern University’s Feinberg School of Medicine. Paller mentioned that taking the drug will significantly improve the quality of life of babies and young children with the disease. He also said that eczema or atopic dermatitis is not just itchy skin, it is a devastating disease, severe eczema can have a huge impact on the quality of life of children and their parents.
Paller noted that based on the results of the study, the drug is now available for 6-month-old babies and preschoolers. It has an excellent safety profile and does not require any laboratory tests even before starting the medication. He also said that they should not use immunosuppressive drugs, such as oral steroids, when they are treating severe eczema and that they should try to avoid using them in children because they are associated with many side effects. Paller is concerned about the long-term effects of immunosuppressants on the development of the immune system in young children, so it is not the treatment of choice.
The drug dupilumab, developed over the past few years, is the first targeted “biological drug” to treat eczema and has been found to be effective and safe in studies of adults, teenagers and other school-aged children. In addition, the drug has been shown to be effective in the treatment of asthma, allergic gastrointestinal manifestations and other allergic problems, but is not approved for these indications in infants and young children.
But Paller was concerned that people under the age of 5 had not been tested for the drug, so they ran a trial: Parents and health care providers gave their children monthly injections of the drug. The results showed that the effect of the treatment was significantly. , drugs without inhibitors work just as well.
In the trial, 66% of the children developed eczema within 6 months of life, and more than 80% had developed at least 1 allergic disorder, such as asthma or food allergy. Paller said that by treating the immune systems of these young children with severe eczema more aggressively, a range of allergies could be reduced, which would not only change the eczema, but change their lives. Paller said the findings could allow scientists and doctors to better understand the relationship between eczema and various allergic conditions, and consider using the drug for other conditions in young children.
No need to take a picture, no need to grab, now use the APP to watch the news to make sure you win the prize every day, I download the APP and press me to watch the method of the event